naftin Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Naftin, and when can generic versions of Naftin launch?
Naftin is a drug marketed by Sebela Ireland Ltd and is included in three NDAs. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has three patent family members in three countries.
The generic ingredient in NAFTIN is naftifine hydrochloride. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the naftifine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Naftin
A generic version of naftin was approved as naftifine hydrochloride by TARO on January 6th, 2016.
Summary for naftin
| International Patents: | 3 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 8 |
| Patent Applications: | 738 |
| Drug Prices: | Drug price information for naftin |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for naftin |
| What excipients (inactive ingredients) are in naftin? | naftin excipients list |
| DailyMed Link: | naftin at DailyMed |
Recent Clinical Trials for naftin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Therapeutics, Inc. | Phase 1 |
| Semler Research Center Pvt. Ltd. | Phase 3 |
| Genzum Life Sciences | Phase 3 |
Pharmacology for naftin
| Drug Class | Allylamine Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for naftin
Paragraph IV (Patent) Challenges for NAFTIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| NAFTIN | Gel | naftifine hydrochloride | 2% | 204286 | 1 | 2015-02-04 |
US Patents and Regulatory Information for naftin
naftin is protected by six US patents.
Patents protecting naftin
Topical compositions and methods for making and using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical compositions and methods for making and using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical compositions and methods for making and using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical compositions and methods for making and using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical compositions and methods for making and using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical compositions and methods for making and using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF FUNGAL INFECTIONS
Expired US Patents for naftin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | NAFTIN | naftifine hydrochloride | GEL;TOPICAL | 019356-001 | Jun 18, 1990 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | NAFTIN | naftifine hydrochloride | CREAM;TOPICAL | 019599-001 | Feb 29, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | NAFTIN | naftifine hydrochloride | GEL;TOPICAL | 019356-001 | Jun 18, 1990 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for naftin
See the table below for patents covering naftin around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1092158 | CINNAMYL-ALKYL-1-NAPTHYLAMINES (CINNAMYL-ALKYL-1-NAPHTHYLAMINES) | ⤷ Try a Trial |
| Netherlands | 7704401 | ⤷ Try a Trial | |
| Philippines | 16489 | CINNAMYLALKYL-1-NAPHTHYLMETHYL AMINES,CHEMOTHERAPEUTIC COMPOSITIONS CONTAINING THEM AND THE USE AS ANTIMYCOTICS | ⤷ Try a Trial |
| South Africa | 7702564 | ⤷ Try a Trial | |
| United Kingdom | 1579879 | ⤷ Try a Trial | |
| Japan | S6149297 | ⤷ Try a Trial | |
| Austria | 362348 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
